Viewing StudyNCT04422912



Ignite Creation Date: 2024-05-06 @ 2:47 PM
Last Modification Date: 2024-10-26 @ 1:37 PM
Study NCT ID: NCT04422912
Status: RECRUITING
Last Update Posted: 2024-05-22
First Post: 2020-06-02

Brief Title: A Phase 12 Open-label Safety and Dosing Study of Autologous CART Cells Desmoglein 3 Chimeric Autoantibody Receptor T Cells DSG3-CAART or CD19-specific Chimeric Antigen Receptor T Cells CABA-201 in Subjects With Active Pemphigus Vulgaris RESET-PV
Sponsor: Cabaletta Bio
Organization: Cabaletta Bio

Conditions & Keywords Data

Conditions:
Name
Pemphigus Vulgaris
Keywords:
Name View
Pemphigus View
Pemphigus Vulgaris View
CAAR-T Therapy View
CAR-T Therapy View
Desmoglein 3 View
Cell Therapy View
Autoimmune Disease View
Autoimmunity View
Skin Diseases Vesiculobullous View
Immunotherapy Adoptive View
Immune System Diseases View
CABA-201 View
Anti-CD19 CAR-T therapy View